FdaApplication
NDA 210361
Identifiers
- fda_app_no: NDA210361
Properties
| Property | Value |
|---|---|
| applicant_name | JOURNEY MEDICAL CORP |
| application_type | NDA |
| approval_date | 2018-06-28 |
Revenue by product
QBREXZA
| Period | Revenue |
|---|---|
| Q2 2026 | $5.1M |
| Q1 2026 | $5.0M |
| Q4 2025 | $5.5M |
| Q3 2025 | $7.4M |
| Q2 2025 | $6.9M |
| Q1 2025 | $5.2M |
| Q4 2024 | $5.7M |
| Q3 2024 | $7.6M |
| Q2 2024 | $6.8M |
| Q1 2024 | $5.0M |
| Q4 2023 | $7.4M |
| Q3 2023 | $5.9M |
| Q2 2023 | $8.1M |
| Q1 2023 | $4.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| QBREXZA | GLYCOPYRRONIUM TOSYLATE | EQ 2.4% BASE | CLOTH;TOPICAL |
1 product